ado-trastuzumab emtansine (Kadcyla, T-DM1)
Jump to navigation
Jump to search
Indications
- HER2-positive metastatic breast cancer unresponsive to trastuzumab plus chemotherapy
Contraindications
Adverse effects
- liver toxicity, heart toxicity & death (boxed warning)
- severe life-threatening birth defects
Notes
- distinguish from trastuzumab (Herceptin) with different dosage & treatment schedules[3]
More general terms
References
- ↑ FDA News Release: Feb. 22, 2013 FDA approves new treatment for late-stage breast cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm
- ↑ Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23020162
- ↑ 3.0 3.1 FDA MedWarch. May 6, 2013 Kadcyla (ado-trastuzumab emtansine): Drug Safety Communication
Potential Medication Errors Resulting from Name Confusion. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350817.htm